Leuprolide pharmacokinetics

Shahiwala, A., and Misra, A. (2005), A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler A technical note, AAPS PharmSciTech., 6, E482-486. 

Leuprolide acetate, a synthetic nonapeptide, is prescribed for the treatment of metastatic prostate cancer and endometriosis. Leuprolide acetate is presented in a number of injectable dosage forms including Lupron sterile solution for subcutaneous administration (1 and 5 mg mL 1) and Lupron depot controlled release formulation for intramuscular injection (3.75 and 7.5 mg). Zheng and Fulu [106] have evaluated the in vivo effect of leuprolide loaded micro emulsions on the genital organs of the male and female rats. In the preliminary pharmacokinetic studies, oral microemulsions of leuprolide administration resulted in 10-fold higher plasma levels of leuprolide as compared to that of saline solution (Fig. 9.4). 

In vitro Permeation Study of Leuprolide 6313 Clinical Pharmacokinetics of Depot Leuprolide... 

In this section, the pharmacokinetics of clinically important peptide/protein drugs, such as insulin, EPO, G-CSF, interferon, growth hormone, leuprolide, desmopressin, and antibodies, are described in relation to their administration routes and formulations (i.e., dosage forms). 

Okada, H., Inoue, Y., Heya, T., Ueno, H., Ogawa, Y., andToguchi, H., 1991, Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate, Pharm. Res. 8 787-791. 

Shahnaz G, et al. Thiolated chitosan nanoparticles for the nasal administration of leuprolide BioavaUability and pharmacokinetic characterization. Int J Pharm. 2012 428(1—2) 164—70. 

---